

# Division of Workers' Compensation Pharmacy and Therapeutics Committee

July 16, 2025  
12:30pm to 2:30pm



State of California  
Gavin Newsom  
Governor

# Agenda

- **Welcome and Introductions**  
George Parisotto, Administrative Director, DWC
- **Approval of January 15, 2025 Meeting Minutes**  
Dr. Raymond Meister, Executive Medical Director, DWC
- **MTUS Drug List v13**  
Dr. Raymond Meister
- **Discussion:**
  - MD Guidelines Recommendation and Evidence Ratings – *Kevin Gorospe Pharm D*
  - Topical Analgesic Evidence Review – *Kevin Gorospe Pharm D*
  - Topical Analgesic Utilization and Cost Review – *Kevin Gorospe Pharm D*
- **Additional Public Comments**
- **Review of Committee Recommendations**
- **Adjourn**

# Welcome and Introductions

George Parisotto

Administrative Director, DWC

# Approval of January 15, 2025 Meeting Minutes

Dr. Raymond Meister  
Executive Medical Director, DWC

# MTUS Drug List v13

Dr. Raymond Meister

Executive Medical Director, DWC

# MD Guidelines Recommendations and Evidence Ratings

J. Kevin Gorospe, PharmD  
DWC Consultant



State of California  
Gavin Newsom  
Governor

# Review of Recommendations and Evidence

- A review of the MTUS Guidelines for both topical anesthetics (lidocaine containing products) and NSAIDs (diclofenac
- The review identified the conditions for which the drugs had a recommendation for use
- Conditions with a not recommended or no recommended were not reviewed
- The rational for use and drugs used in the supporting studies were identified and summarized

# Recommendation Categories

Recommendation Category	Evidence Rating	Description of Category
Strongly Recommended	A	The intervention is strongly recommended for appropriate patients. The intervention improves important health and functional outcomes based on high quality evidence, and the Evidence-Based Practice Panel (EBPP) concludes that benefits substantially outweigh harms and costs.
Moderately Recommended	B	The intervention is recommended for appropriate patients. The intervention improves important health and functional outcomes based on moderate quality evidence that benefits substantially outweigh harms and costs.
Recommended	C	The intervention is recommended for appropriate patients. There is limited evidence that the intervention may improve important health and functional benefits.
Consensus* Recommended	I	The intervention is recommended for appropriate patients and has nominal costs and essentially no potential for harm.* The EBPP feels that the intervention constitutes best medical practice to acquire or provide information in order to best diagnose and treat a health condition and restore function in an expeditious manner. The EBPP believes based on the body of evidence, first principles, and/or collective experience that patients are best served by these practices, although the evidence is insufficient for an evidence-based recommendation.
Consensus* Sometimes Recommended	I	The intervention may be for appropriate to trial for a select group of patients, typically after other interventions have failed. For most patients, the evidence for the intervention lacks efficacy, is of poor quality, or is conflicting and the balance of benefits, harms, and costs cannot be determined.



# Recommendation Categories (Continued)

Recommendation Category	Evidence Rating	Description of Category
Consensus* No Recommendation	I	The evidence is insufficient to recommend for or against routinely providing the intervention. The EBPP makes no recommendation. Evidence that the intervention is effective is lacking, of poor quality, or conflicting and the balance of benefits, harms, and costs cannot be determined.
Consensus* NOT Recommended	I	The evidence is insufficient for an evidence-based recommendation. Evidence that the intervention is effective is lacking, of poor quality, or conflicting and the balance of benefits, harms, and costs cannot be determined.
NOT Recommended	C	Recommendation against routinely providing the intervention. The EBPP found at least moderate evidence that harms and costs exceed benefits based on limited evidence.
Moderately NOT Recommended	B	Recommendation against routinely providing the intervention to eligible patients. The EBPP found at least moderate evidence that harms and costs outweigh benefits.
Strongly NOT Recommended	A	Strong recommendation against providing the intervention to eligible patients. The EBPP found high-quality evidence that the intervention is ineffective, or that harms or costs outweigh benefits.

# Referenced Studies

- The guidelines provides references for their recommendations.
- Studies are scored using the Ottawa-Newcastle System fall within one of three categories
  - 0-3 low quality studies
  - 4-6 moderate quality studies
  - 7-9 high quality studies
- Unfortunately, not all of the studies in the guidelines have assigned scores
- Some treatments have no referenced studies but use other factors for the recommendation

# Topical Analgesic Evidence Review

J. Kevin Gorospe, PharmD  
DWC Consultant

# Lidocaine Patches (LIDODERM)

J. Kevin Gorospe, PharmD  
DWC Consultant



State of California  
Gavin Newsom  
Governor

# Lidocaine Patches (LIDODERM) (Continued)

- Lidocaine patches are specifically identified in the guidelines
- There were five conditions identified with recommendations for treatment with lidocaine
  - Ankle and Foot Disorders
    - Tarsal Tunnel Syndrome, Acute and Chronic (I)
  - Chronic Pain
    - Neuropathic Pain Chronic (B)
  - Hand, Wrist and Forearm Disorders
    - Carpal Tunnel Syndrome, Acute and Chronic (I)
    - Kienbock Disease, Acute and Chronic (I)
  - Shoulder Disorders
    - Thoracic Outlet Syndrome (B)

# Lidocaine Patches Summary

- Lidocaine patches are not invasive and have a low adverse effects profile
- Lidocaine patches are moderately costly but can be of high cost over time
- Referenced studies used lidocaine 5% patchers

# Lidocaine Evidence Summary

Condition	Evidence Rating	Number of Studies Referenced	Drug Used in Studies
Tarsal Tunnel Syndrome	I	3	lidocaine 5% patch
Neuropathic Pain	B	3	lidocaine 5% patch
Carpal Tunnell Syndrome	I	2	lidocaine 5% patch
Kienbock Disease	I	0	Not Applicable
Thoracic Outlet Syndrome	B	0	Not Applicable

# Lidocaine for Tarsal Tunnel Syndrome (I)

- Topical lidocaine has not been evaluated in quality studies of TTS
- Three referenced studies used 5% lidocaine patches (no scoring provided)
  - 2 studies on carpal tunnel syndrome (CTS)
  - 1 study on postherpetic neuralgia
- Rationale:
  - Support is derived from evidence that lidocaine patches may provide benefit to persons with CTS



# Lidocaine for Neuropathic Pain (B)

- Eight studies listed as evidence all using 5% patches
  - Two with high quality scores of 9 and 7.5, of lidocaine 5% patches vs. placebo
- Rationale:
  - Lidocaine patches have been reportedly effective for treatment of localized peripheral neuropathic pain (5 studies)
  - Topical lidocaine has been suggested to improve pain associated with CTS and appears to be somewhat more effective than naproxen (1 study)
  - Some evidence of efficacy for treatment of carpal tunnel syndrome, and thus are recommended for treatment of peripheral neuropathic pain

# Lidocaine for Carpal Tunnel Syndrome (I)

- Two studies listed as evidence, both of low quality (scores = 4.5)
  - Lidocaine 5% patch vs methylprednisolone depot injection
  - Lidocaine 5% patch vs naproxen 500mg twice daily
- Rationale:
  - In one moderate-quality study, lidocaine patches were suggested to be somewhat more effective than naproxen
  - In the other study, methylprednisolone injection was comparable to the patch
  - While there are other lower cost topical treatments that provide analgesia (including heat, ice, and capsaicin), lidocaine patches may be a reasonable treatment option for pain related to CTS.

# Lidocaine for Kienböck Disease (I)

- No quality studies evaluating the use of topical medications
- Rationale:
  - Topical treatments may provide symptom relief
  - They are non-invasive and have few adverse effects
  - Caution is warranted if there is use of anesthetic agents over large areas of the body, as adverse effects from systemic absorption have been reported.

# Lidocaine for Thoracic Outlet Syndrome (B)

- No quality studies evaluating treatment of TOS
- In the absence of quality evidence, it is recommended that neurogenic TOS and disputed TOS be treated the same as Chronic Neuropathic Pain
- The Evidence Support rating of “B” is from the Chronic Neuropathic Pain evidence and not studies of use in TOS

# Diclofenac Topical Gel (VOLTAREN)

J. Kevin Gorospe, PharmD  
DWC Consultant



State of California  
Gavin Newsom  
Governor

# Diclofenac Topical (VOLTAREN Gel)

- Diclofenac gel is preferred over other topical diclofenac products.
- Diclofenac is not recommended as first or second line due to increased risk for hepatotoxicity.
- Diclofenac is the only FDA approved topical NSAID. All other agents are considered investigational, and use is not recommended
- Topical NSAIDs are not invasive, have low adverse effect rates, but may be moderate to high cost.
- Generally, not to be used continuously, or for more than 1 month.
- May be reasonable to trial in patient who prefer topical treatments over other treatments.

# Diclofenac Summary of Evidence

Condition	Evidence Rating	Number of Studies Referenced	Drug(s) Used in Studies
Achilles Tendinopathy	Acute (C) Chronic (I)	2	piroxicam gel niflumic gel
Ankle Sprain	Acute (B)	6	ketoprofen patch diclofenac gel ketorolac gel etofenamate gel
Ankle Tendinopathy other than Achilles	Acute (C) Chronic (I)	0	Not Applicable
Midtarsus Sprain	Acute (I)	0	Not Applicable
Plantar Faciitis	Acute and Chronic (I)	0	Not Applicable
Complex Regional Pain Syndrome	Chronic (I)	1	diclofenac lotion

# Diclofenac Summary of Evidence (Continued)

Condition	Evidence Rating	Number of Studies Referenced	Drug(s) Used in Studies
Neuropathic Pain	Chronic (C)	1	diclofenac lotion
Lateral Epicondylalgia	Acute (B), Chronic (B), Acute Post Op (I)	4	Diclofenac hydroxyethylpyrrolidine flurbiprofen patch and piroxicam gel diclofenac gel
Medial Epicondylalgia	Acute and Chronic (I)	0	Not Applicable
Extensor Compartment Tenosynovitis	Acute and Chronic (C)	3	ketoprofen patch nimesulide diclofenac gel
Hand/Finger Osteoarthritis	Acute and Chronic (I)	4	trolamine salicylate diclofenac gel
Kienbock Disease	Acute and Chronic (I)	0	Not Applicable
Thoracic Outlet Syndrome	Chronic (C)	0	Not Applicable



# Conditions for Diclofenac Topical Use

- Ankle and Foot Disorders
  - Achilles Tendinopathy, Acute (C) and Chronic (I)
  - Ankle Sprain, Acute (B)
  - Ankle Tendinopathy other than Achilles, Acute (C) and Chronic (I)
  - Midtarsus Sprain, Acute (I)
  - Plantar Faciitis, Acute and Chronic (I)
- Chronic Pain
  - Complex Regional Pain Syndrome (CPRS), Chronic (I)
  - Neuropathic, Chronic (C)
- Elbow Disorders
  - Lateral Epicondylalgia, Acute and Chronic (B), and Acute Post Op (I)
  - Medial Epicondylalgia, Acute and Chronic (I)
- Hand, Wrist, Forearm Disorders
  - Extensor Compartment Tenosynovitis, Acute and Chronic (C)
  - Hand/Finger Osteoarthritis, Acute and Chronic (I)
  - Kienbock Disease, Acute and Chronic (I)
- Shoulder Disorders
  - Thoracic Outlet Syndrome, Chronic (C)

# Achilles Tendinopathy, Acute (C) and Chronic (I)

- Two moderate quality studies listed showing superiority over placebo
  - piroxicam gel vs. placebo
  - niflumic acid gel vs. placebo (not available in US)
- Rationale:
  - There is one moderate-quality placebo-controlled trial that found efficacy of treatment with topical niflumic acid for Achilles tendon disorders
  - trial that used piroxicam to treat Achilles tendonitis also suggested efficacy; however, it included a small minority of Achilles tendinitis (3%)
  - There is no evidence of efficacy in patient with chronic Achilles tendinosis.

# Ankle Sprain, Acute (B)

- There are 3 high- and 3 moderate-quality placebo-controlled randomized trials listed for the use of topical NSAIDs in the treatment of ankle sprain injuries
- Rationale:
  - All 3 high-quality RCTs demonstrated treatment benefit in analgesia and swelling reduction using daily ketoprofen patch, diclofenac gel, and ketorolac or etofenamate gel in placebo controlled trials
  - Moderate-quality – one study showed no benefit of piroxicam gel over placebo; second study found niflumic acid gel to provide benefit in pain and function improvement; third study no effect with flurbiprofen patch vs. placebo
- Recommended for treatment of acute ankle sprain, particularly in patients who do not tolerate or are poor candidates for oral treatment

# Ankle Tendinopathy other than Achilles, Acute (C) and Chronic (I)

- Guidelines refer reader to Tenosynovitis treatment
- Rationale:
  - There are no quality studies that address the use of NSAIDs controlling pain associated with ankle compartment tenosynovitis.
  - NSAIDs are often used to treat pain associated with wrist compartment tendinoses with one quality study demonstrating efficacy of a ketoprofen patch versus placebo
  - Because NSAID patch has been demonstrated to be efficacious compared to placebo for the wrist, it is assumed that other topical forms are also efficacious

# Midtarsus Sprain, Acute (I)

- There are no quality studies on these sprains
- Treatment recommendations are by analogy to ankle sprain

# Plantar Faciitis, Acute and Chronic (I)

- There are no quality trials of topical NSAIDs for treatment of plantar heel pain
- Rationale:
  - Support is derived from evidence that topical NSAIDs may provide benefit to persons with Achilles tendinopathy

# Complex Regional Pain Syndrome (CPRS), Chronic (I)

- One placebo-controlled trial among heterogenous patients (including post-herpetic neuralgia and an unclear proportion with CRPS) comparing topical diclofenac lotion to placebo
- Rationale:
  - Data suggests topical NSAIDs may be an effective treatment, but the heterogeneity of the study group limits ability to generalize results
  - Support derived from evidence that NSAIDs are effective in treatment of other pain conditions

# Neuropathic Pain, Chronic (C)

- Target tissue for neuropathic pain is often too deep for clear justification of use of topical NSAID, therefore topical NSAIDs are recommended for neuropathic pain with superficial pain generation
- References same study used for CPRS evidence
- Rationale:
  - There is one moderate-quality trial showing efficacy of diclofenac lotion 1.5% for treatment of neuropathic pain from post-herpetic neuralgia and CRPS
  - Evidence of efficacy for post-herpetic neuralgia, and therefore are recommended for neuropathic pain with superficial pain generation



# Lateral Epicondylalgia, Acute (B), Chronic (B), and Acute Post Op (I)

- Four studies listed as evidence
  - One used DHEP vs Placebo, one used flurbiprofen patch vs piroxicam gel and the other 2 were diclofenac gel vs placebo
- Rationale:
  - DHEP and diclofenac studies suggest efficacy of topical NSAIDs in reducing pain

# Medial Epicondylalgia, Acute and Chronic (I)

- There are no studies on use of NSAIDs in medial epicondylalgia
- Recommendations based on evidence and use in treatment of lateral epicondylalgia

# Extensor Compartment Tenosynovitis, Acute and Chronic (C)

- NSAIDs (oral or topical) are recommended to control pain associated with acute, subacute, or chronic extensor compartment tenosynovitides
- Two high quality and one moderate quality studies listed as evidence
  - One high quality study used ketoprofen patch, the other used nimesulide and the moderate quality study used diclofenac gel
- Rationale
  - As an NSAID patch has been demonstrated to be efficacious compared to placebo, it is assumed that other topical forms are also efficacious.

# Hand/Finger Osteoarthritis, Acute and Chronic (I)

- Four high quality and one moderate quality studies listed as evidence
  - High quality studies used trolamine salicylate or diclofenac gel
  - Moderate quality study used trolamine salicylate.
  - The trolamine salicylate studies are single-application studies precluding an evaluation is a regular treatment regimen, although they do suggest weak efficacy
- Rationale:
  - Topical NSAIDs have been widely used for hand and finger pain
  - One diclofenac study showed it was superior to placebo

# Kienbock Disease, Acute and Chronic (I)

- No quality studies evaluating the use of topical medications
- Rationale:
  - Topical treatments may provide symptom relief
  - They are non-invasive and have few adverse effects
- Caution is warranted if there is use of anesthetic agents over large areas of the body, as adverse effects from systemic absorption have been reported.

# Thoracic Outlet Syndrome, Chronic (C)

- No quality studies evaluating treatment of TOS
- In the absence of quality evidence, it is recommended that neurogenic TOS and disputed TOS be treated the same as Chronic Neuropathic Pain
- The Evidence Support rating of “B” is from the Chronic Neuropathic Pain evidence and not studies of use in TOS

# Committee Discussion

# Public Comments



# Topical analgesic utilization and cost review

J. Kevin Gorospe, PharmD  
DWC Consultant



State of California  
Gavin Newsom  
Governor

# Topical Anesthetics

J. Kevin Gorospe, PharmD  
DWC Consultant



State of California  
Gavin Newsom  
Governor

# Topical Anesthetics by Billed Lines (Pharmacy)

- Top 10 NDCs account for 81% of billed lines

NDC Paid	Label Name	Legend Indicator	Billed Lines	Percent of Billed Lines
65162079108	LIDOCAINE 5% PATCH	Y	9,007	22.20%
00591352530	LIDOCAINE 5% PATCH	Y	6,103	15.04%
00603188016	LIDOCAINE 5% PATCH	Y	6,033	14.87%
82347050505	LIDOCAINE 5% PATCH	Y	3,622	8.93%
65162091853	LIDOCAINE 5% OINTMENT	Y	2,951	7.27%
00536120215	LIDOCAINE PAIN RELIEF 4% PATCH	N	1,284	3.16%
69557011130	ZTLIDO 1.8% TOPICAL SYSTEM	Y	1,280	3.15%
50488100101	TEROCIN PATCH	N	964	2.38%
68462041827	LIDOCAINE 5% OINTMENT	Y	907	2.24%
53149210004	NULIDO 4%-1% GEL	N	738	1.82%

# Topical Anesthetics by Billed Lines (Physician)

- Top 10 NDCs account for 97% of billed lines

NDC Paid	Label Name	Legend Indicator	Billed Lines	Percent of Billed Lines
68462041827	LIDOCAINE 5% OINTMENT	Y	6,925	30.28%
65162091853	LIDOCAINE 5% OINTMENT	Y	5,813	25.42%
00603188016	LIDOCAINE 5% PATCH	Y	3,787	16.56%
53225102201	LIDOPRO 4% OINTMENT	N	3,181	13.91%
59088039654	LIDOCAINE 5% PATCH	Y	837	3.66%
50488100101	TEROCIN PATCH	N	477	2.09%
00591352530	LIDOCAINE 5% PATCH	Y	420	1.84%
82347050505	LIDOCAINE 5% PATCH	Y	310	1.36%
53225102001	LIDOPRO 4% OINTMENT	N	249	1.09%
73086090499	LIDOCAINE-MENTHOL 4%-4% PATCH	N	210	0.92%

# Topical Anesthetics by Amount Paid (Pharmacy)

- Top 10 NDCs account for 72% of the total amount paid

NDC Paid	Label Name	Legend Indicator	Total Paid	Percent of Total Paid
65162079108	LIDOCAINE 5% PATCH	Y	\$1,485,348.17	21.91%
00603188016	LIDOCAINE 5% PATCH	Y	\$637,546.20	9.40%
69557011130	ZTLIDO 1.8% TOPICAL SYSTEM	Y	\$541,002.13	7.98%
00591352530	LIDOCAINE 5% PATCH	Y	\$532,393.61	7.85%
50488100101	TEROCIN PATCH	N	\$470,459.55	6.94%
65162091853	LIDOCAINE 5% OINTMENT	Y	\$294,148.90	4.34%
82347050505	LIDOCAINE 5% PATCH	Y	\$263,023.22	3.88%
53225103001	VIVA PATCH	N	\$217,729.19	3.21%
73086090499	LIDOCAINE-MENTHOL 4%-4% PATCH	N	\$211,452.65	3.12%
59088046607	DERMACINRX LIDOGEL 2.8% GEL	Y	\$210,153.24	3.10%

# Topical Anesthetics by Amount Paid (Physician)

- Top 10 NDCs account for 98% of the total amount paid

NDC Paid	Label Name	Legend Indicator	Total Paid	Percent of Total Paid
68462041827	LIDOCAINE 5% OINTMENT	Y	\$886,936.31	31.86%
53225102201	LIDOPRO 4% OINTMENT	N	\$526,011.15	18.89%
65162091853	LIDOCAINE 5% OINTMENT	Y	\$524,829.29	18.85%
50488100101	TEROCIN PATCH	N	\$243,813.58	8.76%
59088039654	LIDOCAINE 5% PATCH	Y	\$243,568.45	8.75%
73086090499	LIDOCAINE-MENTHOL 4%-4% PATCH	N	\$149,176.50	5.36%
53225102001	LIDOPRO 4% OINTMENT	N	\$73,177.59	2.63%
00603188016	LIDOCAINE 5% PATCH	Y	\$46,947.67	1.69%
00591352530	LIDOCAINE 5% PATCH	Y	\$18,164.41	0.65%
68462041820	LIDOCAINE 5% OINTMENT	Y	\$13,935.88	0.50%

# Lidocaine Patch (Pharmacy)

- The Top 10 most utilized NDCs account for 95% of billed lines and 94% of total paid

NDC Paid	Label Name	Lidocaine Strength	Legend Indicator	Billed Lines	Percent of Billed Lines	Total Paid	Percent of Total Paid
65162079108	LIDOCAINE 5% PATCH	5%	Y	9,007	29.38%	\$1,485,348.17	38.85%
00591352530	LIDOCAINE 5% PATCH	5%	Y	6,103	19.91%	\$532,393.61	13.92%
00603188016	LIDOCAINE 5% PATCH	5%	Y	6,033	19.68%	\$637,546.20	16.67%
82347050505	LIDOCAINE 5% PATCH	5%	Y	3,622	11.82%	\$263,023.22	6.88%
00536120215	LIDOCAINE PAIN RELIEF 4% PATCH	4%	N	1,284	4.19%	\$30,937.54	0.81%
69557011130	ZTLIDO 1.8% TOPICAL SYSTEM	1.8%	Y	1,280	4.18%	\$541,002.13	14.15%
46122045021	LIDOCAINE PAIN RELIEF 4% PATCH	4%	N	731	2.38%	\$19,503.61	0.51%
00536120207	LIDOCAINE PAIN RELIEF 4% PATCH	4%	N	537	1.75%	\$13,988.44	0.37%
42858011830	LIDOCAINE 5% PATCH	5%	Y	338	1.10%	\$43,168.75	1.13%
46581083006	SALONPAS 4% PATCH	4%	N	315	1.03%	\$15,805.01	0.41%

# Lidocaine Patch (Physician)

- The Top 10 most utilized NDCs account for 99.6% of billed lines and 98% of total paid

NDC Paid	Label Name	Strength	Legend Indicator	Billed Lines	Percent of Billed Lines	Total Paid	Percent of Total Paid
00603188016	LIDOCAINE 5% PATCH	5%	Y	3,787	69.03%	\$46,947.67	14.17%
59088039654	LIDOCAINE 5% PATCH	5%	Y	837	15.26%	\$243,568.45	73.54%
00591352530	LIDOCAINE 5% PATCH	5%	Y	420	7.66%	\$18,164.41	5.48%
82347050505	LIDOCAINE 5% PATCH	5%	Y	310	5.65%	\$3,520.90	1.06%
65162079108	LIDOCAINE 5% PATCH	5%	Y	51	0.93%	\$8,569.88	2.59%
46122045021	LIDOCAINE PAIN RELIEF 4% PATCH	4%	N	16	0.29%	\$292.68	0.09%
42858011830	LIDOCAINE 5% PATCH	5%	Y	16	0.29%	\$221.38	0.07%
00536120215	LIDOCAINE PAIN RELIEF 4% PATCH	4%	N	13	0.24%	\$159.82	0.05%
00591267930	LIDOCAINE 5% PATCH	5%	Y	11	0.20%	\$1,022.66	0.31%
69557011130	ZTLIDO 1.8% TOPICAL SYSTEM	1.8%	Y	5	0.09%	\$1,907.27	0.58%



# Lidocaine Patch New Reimbursement Rate

- For Pharmacy dispensed prescriptions
  - Under new rates (effective July 1, 2025) the drug cost per day ranges from 17-cents to \$53.68; majority of the NDCs are below \$4 per day
  - The top 10 most utilized NDCs have a drug cost per day range from 17-cents to \$17.21; Excluding the one high cost NDC, the range is from 17-cents to \$3.44
- For Physician dispensed prescriptions
  - Dispensed quantities are not reported
  - New rates range from 57-cents to \$51 per unit, with most under \$3 per patch

# Lidocaine Other Topicals

- Pharmacy Dispensed
  - Only one product (low usage) contains something other than lidocaine
  - Dosage forms include creams, ointments, liquids and gels
  - The Top 10 most utilized NDCs account for 87% of billed lines and 85% of total paid in this group
  - 8 of the 10 NDCs are 5% ointment, one is 4% cream and one is 2.8% gel
- Physician Dispensed
  - Dosage forms include creams and ointments with ointments most often utilized
  - The Top 5 most utilized NDCs account for 99% of billed lines and 99% of total paid in this group
    - Two NDCs account for 96% of the billed lines and 98% of the total paid

# Lidocaine Other Topicals (Pharmacy)

NDC Paid	Label Name	Legend Indicator	Billed Lines	Percent of Billed Lines	Total Paid	Percent of Total Paid
65162091853	LIDOCAINE 5% OINTMENT	Y	2,951	43.42%	\$294,148.90	20.82%
68462041827	LIDOCAINE 5% OINTMENT	Y	907	13.34%	\$192,647.98	13.64%
51672300805	LIDOCAINE 5% OINTMENT	Y	538	7.92%	\$95,125.33	6.73%
51672302009	LIDOCAINE 5% OINTMENT	Y	388	5.71%	\$120,684.64	8.54%
70752011304	LIDOCAINE 5% OINTMENT	Y	334	4.91%	\$128,479.68	9.09%
51672302002	LIDOCAINE 5% OINTMENT	Y	229	3.37%	\$78,125.57	5.53%
65162091838	LIDOCAINE 5% OINTMENT	Y	165	2.43%	\$45,434.05	3.22%
59088046607	DERMACINRX LIDOGEL 2.8% GEL	Y	153	2.25%	\$210,153.24	14.88%
39328002430	LIDOCAINE 4% CREAM	N	138	2.03%	\$13,000.19	0.92%
16714087802	LIDOCAINE 5% OINTMENT	Y	103	1.52%	\$29,622.14	2.10%

# Lidocaine Other Topicals (Physician)

NDC Paid	Label Name	Legend Indicator	Billed Lines	Percent of Billed Lines	Total Paid	Percent of Total Paid
68462041827	LIDOCAINE 5% OINTMENT	Y	6,925	52.44%	\$886,936.31	61.31%
65162091853	LIDOCAINE 5% OINTMENT	Y	5,813	44.02%	\$524,829.29	36.28%
68462041820	LIDOCAINE 5% OINTMENT	Y	151	1.14%	\$13,935.88	0.96%
65162091838	LIDOCAINE 5% OINTMENT	Y	126	0.95%	\$4,453.07	0.31%
51672300805	LIDOCAINE 5% OINTMENT	Y	105	0.80%	\$3,581.34	0.25%

# Lidocaine Other Topicals New Reimbursement Rate

- For Pharmacy dispensed prescriptions
  - Under new rates the drug cost per day ranges from 12-cents to \$60.64; Majority of the NDCs are below \$3 per day
  - Four NDCs have high per day costs exceeding \$30 per day
  - The top 10 most utilized NDCs have a drug cost per day range from 36-cents to \$53.85; excluding the one high cost NDC, the range is from 36-cents to \$1.62 per day
- For Physician dispensed prescriptions
  - New rates range from 15-cents to \$1.07 per unit which would be comparable to the lower cost per day pharmacy dispensed products

# Lidocaine Combination Products

- The Top 10 most utilized NDCs account for 95% of billed lines and 95% of total paid in this group

NDC Paid	Label Name	Generic Name	Dosage Form	Lidocaine Strength	Legend Indicator	Billed Lines	Percent of Billed Lines	Total Paid	Percent of Total Paid
50488100101	TEROCIN PATCH	LIDOCAINE/MENTHOL	PATCH	4%	N	964	30.89%	\$470,459.55	30.46%
53149210004	NULIDO 4%-1% GEL	LIDOCAINE/MENTHOL	GEL	4%	N	738	23.65%	\$107,607.80	6.97%
53225102001	LIDOPRO 4% OINTMENT	LIDOCAINE HCL/ME SAL/CAP/MENTH	OINTMENT	4%	N	315	10.09%	\$129,888.77	8.41%
73086090499	LIDOCAINE-MENTHOL 4%-4% PATCH	LIDOCAINE/MENTHOL	PATCH	4%	N	278	8.91%	\$211,452.65	13.69%
53225103001	VIVA PATCH	LIDOCAINE/ME- SALICYLAT/CAMPBOR	PATCH	2.5%	N	210	6.73%	\$217,729.19	14.10%
81902010415	ZYLOTROL 4%-1% PATCH	LIDOCAINE/MENTHOL	PATCH	4%	N	146	4.68%	\$32,501.01	2.10%
83881040130	LIDOPRO 4%-0.5%-0.1% PATCH	LIDOCAINE/METHYL SAL/MENTHOL	PATCH	4%	N	145	4.65%	\$178,565.29	11.56%
53225102301	LIDOPRO PATCH	LIDOCAINE/METHYL SAL/MENTHOL	PATCH	4%	N	64	2.05%	\$62,554.58	4.05%
70512001315	LENZAPRO FLEX 4%-4% PATCH	LIDOCAINE HCL/MENTHOL	PATCH	4%	N	61	1.95%	\$61,737.67	4.00%
00168035730	LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM	LIDOCAINE/PRILOCAINE	LIQUID	2.5%	Y	34	1.09%	\$1,064.72	0.07%

# Lidocaine Combination Products (Continued)

- For Pharmacy dispensed prescriptions
  - Under new rates the drug cost per day ranges from 19-cents to \$1320
  - Only one of the Top 10 combination products has a cost per day below a dollar; all others have very high costs or new cost information wasn't available
- For Physician dispensed prescriptions
  - Includes ointments, gels and patches
  - Under new rates the drug cost per day ranges from 28-cents to \$3644
  - Only one of the Top 10 combination products has a cost per day below a dollar; all others have very high costs or new cost information wasn't available
- Only combination product on the MTUS is lidocaine/prilocaine (EMLA)

# Lidocaine/Prilocaine

## PHARMACY DISPENSED

NDC Paid	Label Name	Dosage Form	Lidocaine Strength	Billed Lines	Total Paid	Drug Supplies Days	Average Paid per Day	New Drug Price per Day
00168035730	LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM	LIQUID	2.5%	34	\$1,064.72	1,023	\$0.03	\$0.52
00574204230	LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM	CREAM	2.5%	21	\$671.28	852	\$0.04	\$0.49
62332058231	LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM	CREAM	5%	3	\$71.87	90	\$0.27	\$0.47
63739005466	LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM	CREAM	2.5%	2	\$38.07	45	\$0.42	\$0.44

## PHYSICIAN DISPENSED

NDC Paid	Label Name	Dosage Form	Strength	Legend Indicator	Billed Lines	Percent of Billed Lines	Total Paid	Percent of Total Paid	New Drug Price per Unit
00168035730	LIDOCAINE-PRILOCAINE 2.5%-2.5% CREAM	LIQUID	3%	Y	10	0.24%	\$79.02	0.01%	0.27913



# Topical NSAIDs

J. Kevin Gorospe, PharmD  
DWC Consultant



State of California  
Gavin Newsom  
Governor

# Topical NSAID by Billed Lines (Pharmacy)

- 10 NDCs account for 96 percent of billed lines

NDC Paid	Label Name	Legend Indicator	Billed Lines	Percent of Billed Lines
69097052444	DICLOFENAC SODIUM 1% GEL	Y	19,381	47.33%
43598097710	DICLOFENAC SODIUM 1% GEL	N	10,502	25.65%
21922004409	DICLOFENAC SODIUM 1% GEL	N	3,685	9.00%
58602060407	DICLOFENAC SODIUM 1% GEL	N	1,417	3.46%
45802095301	DICLOFENAC SODIUM 1% GEL	N	1,358	3.32%
69097072044	DICLOFENAC SODIUM 1% GEL	N	1,142	2.79%
13107026947	DICLOFENAC 2% SOLUTION PUMP	Y	1003	2.45%
00536129434	DICLOFENAC SODIUM 1% GEL	N	382	0.93%
00536129497	DICLOFENAC SODIUM 1% GEL	N	312	0.76%
21922000909	DICLOFENAC SODIUM 1% GEL	Y	132	0.32%

# Topical NSAID by Billed Lines (Physician)

- 10 NDCs account for 99 percent of billed lines

NDC Paid	Label Name	Legend Indicator	Billed Lines	Percent of Billed Lines
43598097710	DICLOFENAC SODIUM 1% GEL	N	6,731	60.61%
65162083366	DICLOFENAC SODIUM 1% GEL	Y	2,855	25.71%
51672135802	DICLOFENAC 1.5% TOPICAL SOLN	Y	742	6.68%
69097052444	DICLOFENAC SODIUM 1% GEL	Y	244	2.20%
21922000909	DICLOFENAC SODIUM 1% GEL	Y	144	1.30%
68180053701	DICLOFENAC 2% SOLUTION PUMP	Y	61	0.55%
21922004409	DICLOFENAC SODIUM 1% GEL	N	59	0.53%
45802095301	DICLOFENAC SODIUM 1% GEL	N	56	0.50%
13107026947	DICLOFENAC 2% SOLUTION PUMP	Y	36	0.32%
65162091174	DICLOFENAC 1.5% TOPICAL SOLN	Y	31	0.28%

# Topical NSAID by Amount Paid (Pharmacy)

- 10 NDCs account for almost 94% of the amount paid
- Some are very low volume with very high pricing

NDC Paid	Label Name	Legend Indicator	Total Paid	Percent of Total Paid
13107026947	DICLOFENAC 2% SOLUTION PUMP	Y	\$1,189,481.09	43.15%
69097052444	DICLOFENAC SODIUM 1% GEL	Y	\$790,645.46	28.68%
43598097710	DICLOFENAC SODIUM 1% GEL	N	\$164,693.36	5.97%
59088036500	XRYLIX 1.5% KIT	Y	\$119,316.39	4.33%
21922004409	DICLOFENAC SODIUM 1% GEL	N	\$99,999.71	3.63%
62332048712	DICLOFENAC 2% SOLUTION PUMP	Y	\$55,216.65	2.00%
70748033501	DICLOFENAC 2% SOLUTION PUMP	Y	\$51,623.75	1.87%
68180053701	DICLOFENAC 2% SOLUTION PUMP	Y	\$48,209.57	1.75%
59088034300	DERMACINRX LEXITRAL PHARMAPAK	Y	\$36,484.30	1.32%
69097072044	DICLOFENAC SODIUM 1% GEL	N	\$23,042.79	0.84%

# Topical NSAID by Amount Paid (Physician)

- 10 NDCs account for almost 96% of the amount paid

NDC Paid	Label Name	Legend Indicator	Total Paid	Percent of Total Paid
43598097710	DICLOFENAC SODIUM 1% GEL	N	\$53,021	24.70%
68180053701	DICLOFENAC 2% SOLUTION PUMP	Y	\$42,994	20.03%
65162083366	DICLOFENAC SODIUM 1% GEL	Y	\$36,656	17.08%
59088037210	DICLOFENAC 1.5% TOPICAL SOLN	Y	\$21,460	10.00%
51672135802	DICLOFENAC 1.5% TOPICAL SOLN	Y	\$17,848	8.32%
13107026947	DICLOFENAC 2% SOLUTION PUMP	Y	\$11,223	5.23%
00574016712	DICLOFENAC 2% SOLUTION PUMP	Y	\$7,481	3.49%
70512081005	DICLOFENAC 1.5% TOPICAL SOLN	Y	\$5,985	2.79%
69097052444	DICLOFENAC SODIUM 1% GEL	Y	\$5,558	2.59%
50742030805	DICLOFENAC 1.5% TOPICAL SOLN	Y	\$3,687	1.72%

# Diclofenac Gel (Pharmacy)

- Top ten most utilized NDCs account for 97% of billed lines and 98% of amount paid

NDC Paid	Label Name	Legend Indicator	Billed Lines	Percent of Billed Lines	Total Paid	Percent of Total Paid
69097052444	DICLOFENAC SODIUM 1% GEL	Y	19,381	49.11%	\$790,645.46	68.0%
43598097710	DICLOFENAC SODIUM 1% GEL	N	10,502	26.61%	\$164,693.36	14.2%
21922004409	DICLOFENAC SODIUM 1% GEL	N	3,685	9.34%	\$99,999.71	8.6%
58602060407	DICLOFENAC SODIUM 1% GEL	N	1,417	3.59%	\$19,973.40	1.7%
45802095301	DICLOFENAC SODIUM 1% GEL	N	1,358	3.44%	\$19,523.25	1.7%
69097072044	DICLOFENAC SODIUM 1% GEL	N	1,142	2.89%	\$23,042.79	2.0%
00536129434	DICLOFENAC SODIUM 1% GEL	N	382	0.97%	\$6,070.96	0.5%
00536129497	DICLOFENAC SODIUM 1% GEL	N	312	0.79%	\$5,130.08	0.4%
21922000909	DICLOFENAC SODIUM 1% GEL	Y	132	0.33%	\$6,528.58	0.6%
70677112501	FT ARTHRITIS PAIN 1% GEL	N	127	0.32%	\$1,433.24	0.1%

# Diclofenac Gel (Physician)

- Top ten most utilized NDCs account for 99.7% of billed lines and 99.8% of amount paid

NDC Paid	Label Name	Legend Indicator	Billed Lines	Percent of Billed Lines	Total Paid	Percent of Total Paid
43598097710	DICLOFENAC SODIUM 1% GEL	N	6,731	66.14%	\$53,020.95	53.35%
65162083366	DICLOFENAC SODIUM 1% GEL	Y	2,855	28.05%	\$36,656.26	36.88%
69097052444	DICLOFENAC SODIUM 1% GEL	Y	244	2.40%	\$5,557.86	5.59%
21922000909	DICLOFENAC SODIUM 1% GEL	Y	144	1.41%	\$2,145.97	2.16%
21922004409	DICLOFENAC SODIUM 1% GEL	N	59	0.58%	\$1,200.90	1.21%
45802095301	DICLOFENAC SODIUM 1% GEL	N	56	0.55%	\$249.96	0.25%
70677112501	FT ARTHRITIS PAIN 1% GEL	N	18	0.18%	\$56.83	0.06%
63481068403	VOLTAREN 1% GEL	Y	14	0.14%	\$223.56	0.22%
76282066339	DICLOFENAC SODIUM 1% GEL	Y	14	0.14%	\$21.29	0.02%
76282010339	DICLOFENAC SODIUM 1% GEL	N	12	0.12%	\$46.33	0.05%

# Diclofenac Gel New Reimbursement Rate

- For Pharmacy dispensed prescriptions
  - Under new rates the drug cost per day ranges from 33-cents to \$56.71; the top 10 NDCs ranging from 39 to 73 cents per day
  - Excluding these two high-cost products the top per day cost is \$1.23
- For Physician dispensed prescriptions
  - New rates range from 9-cents to 38-cents per unit which would be comparable to the lower cost per day pharmacy dispensed diclofenac gel



# Diclofenac Solution (Pharmacy)

- Top ten NDCs account for 99% of billed lines and 98% of amount paid
- One NDC accounts for 74% of the billed lines and 84% of amount paid

NDC Paid	Label Name	Legend Indicator	Billed Lines	Percent of Billed Lines	Total Paid	Percent of Total Paid
13107026947	DICLOFENAC 2% SOLUTION PUMP	Y	1,003	73.97%	\$1,189,481.09	83.97%
51672135802	DICLOFENAC 1.5% TOPICAL SOLN	Y	83	6.12%	\$3,869.90	0.27%
68180053701	DICLOFENAC 2% SOLUTION PUMP	Y	75	5.53%	\$48,209.57	3.40%
62332048712	DICLOFENAC 2% SOLUTION PUMP	Y	43	3.17%	\$55,216.65	3.90%
65162091174	DICLOFENAC 1.5% TOPICAL SOLN	Y	32	2.36%	\$2,511.72	0.18%
70748033501	DICLOFENAC 2% SOLUTION PUMP	Y	32	2.36%	\$51,623.75	3.64%
51672136908	DICLOFENAC 2% SOLUTION PUMP	Y	28	2.06%	\$8,398.35	0.59%
65162068312	DICLOFENAC 2% SOLUTION PUMP	Y	27	1.99%	\$17,059.53	1.20%
00591214071	DICLOFENAC 1.5% TOPICAL SOLN	Y	8	0.59%	\$16,532.56	1.17%
72603020701	DICLOFENAC 2% SOLUTION PUMP	Y	8	0.59%	\$6,489.47	0.46%

# Diclofenac Solution (Physician)

- Only 11 NDCs, with the top 5 accounting for 97% of the billed lines and 70% of the amount paid
- One NDC accounts for 80% of the billed lines but only 16% of amount paid

NDC Paid	Label Name	Legend Indicator	Billed Lines	Percent of Billed Lines	Total Paid	Percent of Total Paid
51672135802	DICLOFENAC 1.5% TOPICAL SOLN	Y	742	80.13%	\$17,848	15.51%
68180053701	DICLOFENAC 2% SOLUTION PUMP	Y	61	6.59%	\$42,994	37.35%
13107026947	DICLOFENAC 2% SOLUTION PUMP	Y	36	3.89%	\$11,223	9.75%
65162091174	DICLOFENAC 1.5% TOPICAL SOLN	Y	31	3.35%	\$736	0.64%
00574016712	DICLOFENAC 2% SOLUTION PUMP	Y	25	2.70%	\$7,481	6.50%
59088037210	DICLOFENAC 1.5% TOPICAL SOLN	Y	19	2.05%	\$21,460	18.64%
70512081005	DICLOFENAC 1.5% TOPICAL SOLN	Y	7	0.76%	\$5,985	5.20%
50742030805	DICLOFENAC 1.5% TOPICAL SOLN	Y	2	0.22%	\$3,687	3.20%
59088043510	DICLOFENAC 1.5% TOPICAL SOLN	Y	1	0.11%	\$3,687	3.20%
71085000205	DICLOFENAC 1.5% TOPICAL SOLN	Y	1	0.11%	\$0	0.00%
62332048712	DICLOFENAC 2% SOLUTION PUMP	Y	1	0.11%	\$0	0.00%

# Diclofenac Solution New Reimbursement Rate

- For Pharmacy dispensed prescriptions
  - Under new rates the drug cost per day ranges from 54-cents to \$79.98.
  - The 1.5 percent solution shows the lowest drug cost per day apart from one NDC at \$8.11 per day
  - The highest utilized NDC shows a \$4.82 drug cost per day
- For Physician dispensed prescriptions
  - New rates range from 13-cents to 99-cents per unit which would be comparable to the lower cost per day pharmacy dispensed products

# Other NSAID Topical Products

- Pharmacy dispensed:
  - 6 other products were in the utilization data
  - Have very high costs with new drug price per day ranging from \$20.49 to \$156.22
  - Most of these products appear to be premeasured compounding kits
- Physician Dispensed:
  - Only one non-diclofenac product, 10% ketoprofen cream in a compounding kit with a new price of \$13 per unit

# Committee Discussion

# Public Comments

# Review of Recommendations

# Adjournment